Attention-deficit/hyperactivity disorder (ADHD), which causes affected individuals to be impulsive, hyperactive, or inattentive, is typically treated with medications ...
In November, the Boston-based biotech firm Karuna Therapeutics submitted its new schizophrenia medication, called KarXT, to the US Food and Drug Administration for approval. If the agency gives KarXT ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback